University of Münster
CRIS@UM
DE | EN

Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation

Angenendt L, Schliemann C, Lutz M, Rebber E, Schulze AB, Weckesser M, Stegger L, Schäfers M, Groth C, Kessler T, Lenz G, Stelljes M, Berdel WE

Research article (journal) | Peer reviewed

Abstract

Allogeneic stem cell transplantation (alloSCT) is still one of the most powerful tools for the treatment of hematological malignancies. The immune-mediated graft-versus-tumor (GVT) effect endows it with the potential to cure malignancies refractory to all other treatments. Nevertheless, it is associated with the risk of donor cell-mediated graft-versus-host disease (GVHD), which mainly contributes to its relevant morbidity and lethality. © 2016 Macmillan Publishers Limited. All Rights Reserved.

Details about the publication

Journal: Bone Marrow Transplantation
Volume: 51
Issue: 3
Page range: 443-445
Status: Published
Release year: 2016
Language in which the publication is written: English
DOI: 10.1038/bmt.2015.266
Link to the full text: http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84959486445&origin=inward

Authors from the University of Münster

Angenendt, Linus
Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A)
Keßler, Torsten
FB05 - Faculty of Medicine (FB05)
Lutz, Mathias
Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A)
Schliemann, Christoph
Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A)
Schulze, Arik Bernard
Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A)